Premium Exhibitor

Masimo International Sarl

Puits Godet, 10 , 2000 Neuchatel
Switzerland

Telephone +41 32 7201159
Fax +41 32 7241448

Trade fair hall

  • Hall 9 / D60
 Interactive Plan

Hall map

MEDICA 2016 hall map (Hall 9): stand D60

Fairground map

MEDICA 2016 fairground map: Hall 9

Our range of products

Product categories

  • 01  Electromedical equipment / Medical Technology
  • 01.04  Intense medicine / anesthesiology / respiration
  • 01.04.01  Anaesthetic equipment

Anaesthetic equipment

  • 01  Electromedical equipment / Medical Technology
  • 01.04  Intense medicine / anesthesiology / respiration
  • 01.04.01  Anaesthetic equipment
  • 01.04.01.09  Anaesthetic masks, breathing bags

Anaesthetic masks, breathing bags

  • 01  Electromedical equipment / Medical Technology
  • 01.04  Intense medicine / anesthesiology / respiration
  • 01.04.01  Anaesthetic equipment
  • 01.04.01.11  Neuro monitors
  • 01  Electromedical equipment / Medical Technology
  • 01.05  Operating technology and equipment
  • 01.05.04  Operative neuromonitoring

Operative neuromonitoring

  • 01  Electromedical equipment / Medical Technology
  • 01.09  Hospital and Care equipment
  • 01.09.05  Neonatal care equipment

Neonatal care equipment

  • 03  Diagnostics
  • 03.01  Clinical chemistry
  • 03.01.10  Devices and systems for haemoglobin determination

Devices and systems for haemoglobin determination

Our products

Product category: Neuro monitors

Next Generation SedLine® Brain Function Monitor

More Complete Data, Now With An Enhanced Patient State Index        

Next Generation SedLine

Less susceptibility to EMG interference,
by utilising Masimo’s Parallel Signal
Processing Engines to enhance EEG
derived parameters even in the presence
of EMG

Improved Patient State Index (PSI)
performance in low power EEG cases,
using adaptive signal processing that
is not limited by defined bands
 
Reducing Electromyography (EMG) Susceptibility

Next Generation SedLine Brain Function Monitor utilises Masimo’s Parallel Signal Processing Engines to compute an EEG derived parameter including PSI that is less influenced by EMG.
EMG can interfere with EEG signals used in brain function monitoring. Researchers found that EMG interference existed in up to 38% of monitored patients.1,2

More Less

About us

Company details

Masimo (NASDAQ: MASI) is a global medical technology company that develops and manufactures innovative noninvasive patient monitoring technologies, including medical devices and a wide array of sensors. A key medical technology innovator, Masimo is responsible for the invention of award-winning noninvasive technologies that are revolutionizing patient monitoring, including Masimo SET® pulse oximetry, Masimo rainbow® SET Pulse CO-Oximetry and new Masimo noninvasive and continuous total hemoglobin (SpHb®) monitoring technology. These new rainbow® technologies are expected to open new markets and significantly expand the company’s growth opportunities.

Joe Kiani founded Masimo in 1989 as a private "garage start-up" company because he was convinced that the use of adaptive signal processing in the measurement of physiological parameters could solve the problems of low perfusion and motion, which had long plagued in-vivo monitoring and especially pulse oximetry. Today, Masimo has grown into a successful publicly traded medical technology company employing over 2,500 people worldwide with product revenues that have increased 4-fold in the last five years. In addition, the company has technology license and OEM agreements with leading patient monitoring manufacturers spanning the globe including Atom, Datascope, GE Medical, Medtronic, Philips, Spacelabs, and Zoll. Masimo is not only the inventor of Measure-through Motion and Low Perfusion pulse oximetry and Pulse CO-Oximetry technologies, but is also the market-leading pulse oximetry technology solution.

In 1995, Masimo debuted Measure-through Motion and Low Perfusion pulse oximetry, known as Masimo SET—a breakthrough in pulse oximetry technology that virtually eliminated false alarms and increased pulse oximetry’s ability to detect life-threatening events. More than 100 independent and objective studies demonstrate that Masimo SET provides the most reliable SpO2 and pulse rate measurements even under the most challenging clinical conditions, including patient motion and low peripheral perfusion.

In 2005, Masimo introduced rainbow® SET Pulse CO-Oximetry, a breakthrough noninvasive blood constituent monitoring platform that measures many blood constituents that previously required invasive procedures. Masimo rainbow SET continuously and noninvasively measures total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®) and pleth variability index (PVI®), in addition to oxyhemoglobin (SpO2), pulse rate (PR), and perfusion index (PI), enabling early detection and treatment of potentially life-threatening conditions.

For more than 20 years now, Masimo has been focused on a singular mission—to create noninvasive patient monitoring technologies that are more effective and reliable and to improve patient outcomes and reduce the cost of care by bringing these technologies to new sites and applications. The result is a portfolio of clinically-proven products that lead the way in innovation, performance and patient safety by giving health care providers the information they need to optimize clinical decision-making.

More Less

Company data

Number of employees

1000-4999

Foundation

1989

Area of business

Electromedical equipment / Medical Technology